| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Active Research
Forum: Mapping Cancer Markers Forum
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 530
|
|
| Author |
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges: 
|
Cancer Scientists Have Ignored African DNA in the Search for Cures
When a small group of modern humans left Africa 100,000 years ago they left behind a rich genetic diversity. In a Newsweek cover story Charles Rotimi believes that researchers need to capture it, for the benefit of Africa and everyone else. https://www.newsweek.com/2018/07/27/cancer-cu...;_twitter_impression=true  |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
"Double punch" treatment fights lung cancer while reducing kidney damage side effects
Lung cancer is commonly treated with platinum chemotherapy based on a drug called cisplatin. However, less than a third of patients will see any benefit, and often develop serious side effects, including kidney damage. In their research, Professor Neil Watkins (Petre Chair in Cancer Biology, Garvan Institute) and his team, including Dr Kieren Marini (Hudson Institute), found the protein activin to be a primary culprit, both in chemotherapy resistance and chemotherapy-induced kidney damage. Follistatin is a naturally occurring hormone which seems to pack a double punch, not only fighting lung cancer, but preventing the kidney damage common with the traditional cisplatin chemotherapy. The "double punch" treatment was trialed successfully in mice and subsequently published in the journal Science Translational Medicine. The findings are the result of a collaboration between researchers at the Garvan Institute for Medical Research (Sydney) and the Hudson Institute of Medical Research (Melbourne), along with Paranta Biosciences (which is developing follistatin as a potential therapy for cystic fibrosis, kidney disease and now, cancer). The success of their research means this combination strategy is set to move to a clinical setting soon. Follistatin will also be investigated for use with other cancers that use platinum based chemo. More at https://newatlas.com/lung-cancer-treatment-re...dney-damage-side-effects/ |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
How Close Are We, Really to Curing Cancer with CRISPR?
Followers of science and health news, particularly those with a terminal illness, may get the impression that the dawn of a new, disease-free era is upon us and nowhere is this idea more evident than in the latest buzzword in the health sciences, CRISPR. https://www.livescience.com/63192-curing-canc...l?utm_source=notification |
||
|
|
Glen David Short
Senior Cruncher Joined: Nov 6, 2008 Post Count: 185 Status: Offline Project Badges: 
|
New drug puts cancer cells permanently to 'sleep' . Scientists in Melbourne say they have discovered a new type of anti-cancer drug without the usual side effects of conventional cancer treatments. Link
---------------------------------------- [Edit 1 times, last edit by Glen David Short at Aug 2, 2018 11:16:56 PM] |
||
|
|
[VENETO] boboviz
Senior Cruncher Joined: Aug 17, 2008 Post Count: 183 Status: Offline Project Badges: 
|
Philips releases updated TissueMark
----------------------------------------Health technology major Royal Philips has introduced an updated version of its TissueMark computational pathology solution software at Euskalduna Conference Centre in Bilbao, Spain. The new TissueMark version leverages artificial intelligence (AI) to support region of interest detection for molecular testing as well as assists research labs in enhancing the accuracy of tumour estimation. It will also offer tumour sufficiency guidance for lung histology, lung cytology, colon and breast tissue samples along with whole slide images (WSI) of adenocarcinoma prostate tissue as well as high-grade serous carcinoma ovarian tissue [Edit 1 times, last edit by [VENETO] boboviz at Sep 7, 2018 10:04:22 AM] |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
Could Rush to Genomics Damage Public Health?
The race toward "precision public health" (PPH) may jeopardize public health's core mission of enhancing population health, experts argue in a perspective article published online September 5 in the New England of Medicine. https://www.medscape.com/viewarticle/901836?s...p_genomics%26faf%3D1#vp_1 |
||
|
|
AlexGV
Cruncher Russia Joined: Apr 6, 2018 Post Count: 16 Status: Offline Project Badges: 
|
Experimental cancer vaccine combo has 100% success rate in mice
----------------------------------------A promising new cancer vaccine has shown the ability to ward off, and stop the return, of aggressive cancer cells. By adding a molecule called Diprovocim to a vaccine, researchers report being able to draw cancer-fighting cells to tumor sites in mice. It works in conjunction with other cancer-treatment therapies to stop some aggressive, and often deadly, forms of cancer, like melanoma. “This co-therapy produced a complete response — a curative response — in the treatment of melanoma,” said the study’s co-author, Professor Dr. Dale Boger of Scripps Research. The vaccine also prompts the immune system to produce the same targeted response should the cells ever return , according to Boger and Nobel laureate Bruce Beutler, of University of Texas Southern. “Just as a vaccine can train the body to fight off external pathogens, this vaccine trains the immune system to go after a tumor,” Professor Boger writes. So far the research has been tested against a particularly aggressive form of melanoma. After being split into three groups — eight receiving the vaccine, eight receiving the vaccine plus Diprovocim, and eight receiving the vaccine plus an adjuvant called alum — the researchers discovered the mice given the combination of Diprovocim and the vaccine had a 100 percent survival rate of over 54 days. Mice given the cancer vaccine and alum had a 25 percent survival rate, and those given just the vaccine had a zero percent survival rate. When researchers attempted to re-introduce the tumor in mice, “it wouldn’t take,” says Professor Boger. “The animal is already vaccinated against it.” It’s still early days, but the next steps, according to Boger and Beutler, is to do further pre-clinical testing with the vaccine and study its effectiveness when paired with other cancer therapies. https://thenextweb.com/insider/2018/09/11/exp...100-success-rate-in-mice/
i7-3632QM 4C/8T, 2.2GHz (2.9GHz Turbo), 35 W;
i7-3630QM 4C/8T, 2.4 GHz (3.2GHz Turbo), 45 W. |
||
|
|
Jim Slade
Veteran Cruncher Joined: Apr 27, 2007 Post Count: 665 Status: Offline Project Badges:
|
Opening the "black box" of informed consent appointments for genome sequencing: a multisite observational study
Health-care professionals need to be prepared to answer patients' questions about genetics to facilitate genome sequencing consent. Health-care professionals' education also needs to address how to effectively listen and elicit patient's questions and views, and how to discuss uncertainty around the disease risks associated with secondary findings. https://www.nature.com/articles/s41436-018-0310-3#article-info |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Australian Funnel-web spider venom component has low toxicity, skin cancer fighting properties.
----------------------------------------https://newatlas.com/funnel-web-spider-venom-skin-cancer/56671/ [Edit 1 times, last edit by l_mckeon at Oct 9, 2018 1:03:15 AM] |
||
|
|
l_mckeon
Senior Cruncher Joined: Oct 20, 2007 Post Count: 439 Status: Offline Project Badges:
|
Cancer blood test trial hoping to help patients avoid unnecessary chemotherapy
The blood test is called a circulating tumor DNA test (ctDNA), and is designed to identify fragments of tumor DNA. The test was developed in an international collaboration between scientists in the United States and Australia, and early trials have demonstrated extraordinary success in allowing doctors to accurately identify patients most likely to suffer a cancer relapse following surgery. The new trial will focus on both bowel cancer and ovarian cancer patients who have undergone surgery to remove tumors following either stage 2 or stage 3 diagnoses. "We suspect that many women with early stage ovarian cancer can be treated with surgery alone, but we currently treat all these patients as though their cancer may recur, with high dose chemotherapy," explains Sumi Amanda, leading the ovarian cancer arm of the new trial. The trial taking place at more than 40 hospitals in Australia and New Zealand is focused on the association between ctDNA levels found in blood after cancer surgery and the risk of relapse. The hope is that the trial will be able to clearly identify what amount of ctDNA can be correlated with a high risk of relapse. The trials are set to run until around 2021. More at: https://newatlas.com/cancer-blood-test-relapse-risk-chemotherapy-trial/56821/ |
||
|
|
|